Bellicum Pharmaceuticals, Inc. - BLCM STOCK NEWS

Bellicum Pharmaceuticals (NASDAQ:BLCM) has entered into a global option and license agreement with MD Anderson Cancer Center concerning its CaspaCIDe safety switch technology. This agreement allows MD Anderson to incorporate CaspaCIDe into various cellular therapy programs aimed at improving patient outcomes while reducing the risk of adverse events like cytokine release syndrome. Financial terms include upfront payments and royalties on global sales, although specific figures were not disclosed. The partnership aims to leverage this technology to enhance the efficacy of CAR-T cell therapies.

Bellicum Pharmaceuticals reported its second-quarter 2021 results, highlighting a licensing agreement for its CaspaCIDe® technology with leading oncology centers. The company is progressing with clinical trials for BPX-601 and BPX-603, aimed at treating various cancers. R&D expenses decreased to $6.7 million, while net losses narrowed to $2.2 million. Despite a cash position of $21.8 million, Bellicum expects sufficient resources to support operations into Q2 2022. The company remains focused on advancing its next-gen GoCAR-T® therapies.

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced an equity inducement grant of 15,000 stock options to a new employee, effective July 26, 2021. The stock options have an exercise price of $2.86 per share, vesting over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of the Company’s 2019 Equity Incentive Plan. Bellicum focuses on developing controllable cellular immunotherapies for cancer treatment.

Bellicum Pharmaceuticals (NASDAQ:BLCM) has entered a licensing agreement with UNC Lineberger and Mass General for the use of its CaspaCIDe safety switch technology in four CAR-T programs. This deal is expected to enhance patient safety in cell therapies that face risks like cytokine release syndrome. Bellicum will earn upfront payments and royalties from global sales once these programs are out-licensed. The CEO expressed optimism about the potential benefits of CaspaCIDe, which has shown clinical improvement in patients within 24 hours of treatment.

Bellicum Pharmaceuticals (BLCM) reported its Q1 2021 financial results, highlighting continued focus on CAR-T cell therapies. R&D expenses decreased to $6.5 million from $10.4 million YoY, primarily due to reduced rivo-cel activities and corporate restructuring. The company reported a loss from operations of $8.9 million, improved from $14.6 million in Q1 2020. Overall, a net loss of $11.3 million was noted, a sharp contrast to a net income of $17.6 million in the previous year. As of March 31, 2021, cash resources totaled $29.6 million, expected to suffice into Q2 2022.

Bellicum Pharmaceuticals (BLCM) announced key updates, including the initiation of the Phase 1/2 trial for BPX-603 targeting HER2+ solid tumors, and the lifting of a clinical hold on BPX-601 for treating metastatic prostate and pancreatic cancers. Financially, the company reported a Q4 2020 net income of $18.8 million, largely due to a $31.9 million non-cash gain, but a net loss of $7.7 million for the year. R&D expenses decreased significantly to $39.1 million, while cash reserves stood at $37 million, expected to fund operations into Q2 2022.

Bellicum Pharmaceuticals (NASDAQ:BLCM) will report its fourth quarter and full year 2020 financial results on March 30, 2021, after U.S. market close. The management team will host a webcast and conference call at 5 p.m. ET to discuss these results. Bellicum focuses on developing controllable cell therapies for cancer treatment, specifically its GoCAR-T^® candidates, BPX-601 and BPX-603. More details will be accessible on their website after the event.

Bellicum Pharmaceuticals (NASDAQ:BLCM) has announced a breakthrough case report on the use of its CaspaCIDe safety switch in CAR-T therapy, published in the journal Blood. This report highlights a patient from an ongoing Phase 1/2 trial who experienced severe neurologic adverse effects but saw significant improvement after rimiducid was administered, demonstrating the effectiveness of the iC9 safety switch. This is the first clinical use of iC9 in such a scenario, potentially enhancing safety in cellular immunotherapies. CEO Rick Fair expressed confidence in expanding this technology across various programs.

Ponce Therapeutics, Inc. has launched its first R&D program targeting aging-associated skin disorders, focusing on eliminating p16-expressing cells. The company secured laboratory space in Houston, TX, and raised $1,500,000 through a Convertible Note financing led by Rapha Capital Management. This funding will support Ponce's transition into an operational entity. The executive team reunites expertise from the successful IPO of Bellicum Pharmaceuticals, aiming to leverage advancements in aging science for innovative anti-aging solutions.